To be successful as a cancer immunotherapy company, you not only have to be science driven (that’s a given) and offer an approach that could make a difference, you also need a vision and the ability to execute ahead of competitors in a fast moving and competitive landscape.
Dr John Beadle
We’re continuing our series on emerging cancer immunotherapy companies with an in-depth look at PsiOxus, and the vision of CEO Dr John Beadle (pictured right) for it to be a world-leading immuno-oncolytic virus company.
PsiOxus is based just outside of Oxford – it’s part of the so-called “golden triangle,” the area between London, Oxford and Cambridge in the South of England that is a driver of UK science and innovation.
The company is located in a nondescript business park 45 minutes by train from Paddington to Didcot Parkway, followed by a taxi or bus ride. You have to want to make the trip from London!
Dr Beadle kindly spoke to BSB about the competitive advantage the PsiOxus oncolytic virus platform offers, their path-to-market strategy and how he sees the company developing in the future.
With clinical data due in 2017, PsiOxus is a cancer immunotherapy company to watch out for.
Part 1 of the interview focuses on the scientific platform and cancer new products in development that are driving the company forward.
Subscribers can login to read more or you can purchase access.
National Harbor, MD – the 2015 annual meeting of the Society for Immunotherapy of Cancer (SITC) kicked off today with a series of workshops, and mini-symposia before the main meeting starts on Friday.
It is currently glorious weather for Maryland in November, almost too nice to be indoors, which probably means it’s going to be a cold winter for those who live up North!
Of note this afternoon/evening at SITC 2015 was an International Symposium on Cancer Immunotherapy entitled “Today’s Innovators, Tomorrow’s Leaders.”
Organized in collaboration with the World Immunotherapy Council (WIC), the symposium showcased up and coming researchers, each of whom had an expenses paid trip to SITC to present their work before an audience that included many of the “great and good” in cancer immunotherapy. It was useful learn from the questions being asked from the floor too, further adding to the value of the session.
@BernardAFox introduces the International Cancer Symposium and acknowledges the vision behind it.
Dr Bernard A Fox (@BernardAFox), a past President of SITC, in his introduction acknowledged the vision behind it, and in particular, the contribution of Dr Nora Disis (@DrNDisis). Those of you who listen to Novel Targets Podcast heard her in the most recent show.
Today’s daily highlights post offers a few of my “take homes” from this afternoon. It doesn’t discuss unpublished data but some of the presenters went into more detail about posters they are presenting later this week which was interesting.
The symposium was highly enjoyable and well worth attending. Hopefully, it will be repeated at next year’s SITC annual meeting.
Tomorrow here in National Harbor, I’m looking forward to the workshop on new perspective for target antigens in the changing immunotherapy landscape. That will be the subject of tomorrow’s daily digest. Stay tuned!
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.